Navigation Links
GUMC to develop smoking cessation aids based on unconventional nicotine addiction theory
Date:4/21/2010

Washington, DC A Georgetown University Medical Center research team has been awarded a grant from the National Institute on Drug Abuse to discover and develop new smoking cessation drugs based on an unconventional theory about nicotine addiction. Kenneth Kellar, PhD, a professor of pharmacology at GUMC is principal investigator of the five year grant totaling $4.6 million.

The theory, developed in Kellar's lab over the last 20 years, stems from observations that continual administration of nicotine in laboratory animals leads to an increase in the number of nicotinic acetylcholine receptors in the brain. A similar increase in these receptors is seen in the brains of human smokers.

A second important effect of nicotine that has been known for more than 100 years is that it rapidly desensitizes these nicotinic receptors after exposure. Kellar's theory combines both theories: nicotine addiction results from smokers trying to maintain the increased number of brain nicotinic acetylcholine receptors in a desensitized state to avoid over-activity of the increased receptors and the brain circuits they serve.

According to this theory, if a person doesn't smoke for one, two, or three hours, the receptors become active (again), and because smokers have more of these receptors in their brains, this excess activity results in feelings of anxiety. "An addicted smoker has learned that the easiest way to relieve this anxiety is to smoke another cigarette, which then turns off these receptors by desensitizing them. And that starts the cycle again," says Kellar.

"All drug addictions take a toll on life, but nicotine makes the largest impact on health and life expectancy", says Kellar. In fact, according to the Centers for Disease Control, lifelong smokers on average lose more than a decade of life.

The goal of the work supported by this research grant is to discover selective nicotinic receptor desensitizers that can be
'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
215-514-9751
Georgetown University Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. Researchers identify new gene involved in the development of liver cancer
2. Chinese scientists discover marker indicating the developmental potential of stem cells
3. EPA hosts decontamination research and development conference
4. ARS scientists develop self-pollinating almond trees
5. TGen Drug Development accompanies GPEC to BayBio2010
6. New tool developed for DNA research
7. Doubled haploid technology for quickly developing inbred corn lines offered at ISU
8. Study reveals that logging debris suppresses development of an invasive competitor, Scotch broom
9. Researchers develop new method to detect melamine in milk
10. Workshop on R&D for rapid vaccine development and production in Asia/Australia
11. Developing blanket protection from wildfires
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... in New Mexico, nearly every public golf course is ... potable water supplies. Across the U.S. Southwest as a ... treated effluent. Reusing the effluent increases the sustainability of ... alike fertilize their lawns during the growing season. The ... State University turfgrass expert has a new vision for ...
(Date:7/10/2014)... NEW YORK , June 27, 2014 /PRNewswire/ ... against Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: ... action, filed in United States District Court, Middle ... Division, is on behalf of a class consisting ... otherwise acquired Provectus securities between December 17, 2013 ...
(Date:7/10/2014)... CORAL SPRINGS, Florida , July 1, 2014 ... smart wallets pave way for convenience and improved security: NXT-ID, ... Google Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ... ) and MasterCard Corporation (NYSE: MA) NXT-ID, Inc., (OTCQB: ... market, is pleased to announce that the second series of ...
Breaking Biology News(10 mins):'Tailored' water -- the latest in lawn care 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5
... of the Alps, the Andes and the Himalayas in size ... hidden under the world,s oceans. Now in a special issue ... life on these submerged mountain ranges and reveal why these ... bathymetry of our oceans is now resolved at a scale ...
... ARBOR, Mich. -- Physician,s confidence in their abilities to counsel ... to their own personal habits, according to a study by ... depended on a doctor,s own exercise time, being overweight, and ... about diet and exercise. The study, published online ahead ...
... at Huntsman Cancer Institute (HCI) at the University of Utah ... maintenance and repair of the cell,s cytoskeleton, or internal framework, ... The research has implications for cancer, as well as other ... disease. The research was published in the Sep. 14, 2010, ...
Cached Biology News:Marine scientists unveil the mystery of life on undersea mountains 2Doctor's health habits affect patient counseling 2Study offers first explanation of how cells rapidly repair and maintain structure 2
(Date:7/12/2014)... Albany, New York (PRWEB) July 12, 2014 ... market analysis for various reagents used in ... biotechnology is driving the life science reagents ... this study include manufacturers and providers of ... Science Reagents Market Report: http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . ...
(Date:7/11/2014)... , July 11, 2014 , Not ... in, into or from any jurisdiction where to do so ... jurisdiction.  Shire plc ("Shire" or the "Company") (LSE: ... this afternoon.  Shire confirms it has held a meeting with ... by Shire without the prior agreement or approval of AbbVie. ...
(Date:7/11/2014)... 11, 2014 BCC Research ( http://www.bccresearch.com ... POLYMERASE CHAIN REACTION (PCR) TECHNOLOGY: GLOBAL MARKETS , the ... reached nearly $140 billion in 2013. This is estimated ... five-year compound annual growth rate (CAGR) of 28.6%. , ... interesting and exciting possibilities within the broader PCR field. ...
(Date:7/11/2014)... - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today announced that ... use as a once-daily adjunctive therapy for the treatment ... not satisfactorily controlled with conventional therapy.  APTIOM TM ... years of age. Epilepsy is one ... Epilepsy Canada, it affects 0.6% of the population and ...
Breaking Biology Technology:Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3Shire plc - Statement re: Media Speculation 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4
... 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ... has been completed in the Phase II component of ... paclitaxel/carboplatin for patients with advanced cancers. The principal investigators ... Institute of Cancer Research, London, England, and Dr. Geoff ...
... statistical analysis technique that identifies and removes systematic ... could lead to more precise and reliable measurement ... industrial applications. Known as sequential profile adjustment ... the amount of experimental data required to make ...
... SHANGHAI, July 1 /PRNewswire-Asia/ -- WuXi PharmaTech ... had received an award from BASF for,excellent service and outstanding ... ingredients. , (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ... for a good CRO collaboration partner for years, and,today I ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial 2New statistical technique improves precision of nanotechnology data 2New statistical technique improves precision of nanotechnology data 3New statistical technique improves precision of nanotechnology data 4WuXi PharmaTech Receives Award from BASF 2
...
Mouse polyclonal antibody to PRDM2 - PR domain containing 2, with ZNF domain...
Anti Human S14G-Humanin Polyclonal Antibody...
... LABTrack provides a familiar interface for ... and warehousing. The transition from paper ... transparent. LABTrack contains an integrated ... and rules mechanism. These functions allow ...
Biology Products: